Laman UtamaDRUG • CNSX
add
Bright Minds Biosciences Inc
Tutup sebelumnya
$121.62
Julat hari
$119.31 - $123.51
Julat tahun
$33.01 - $170.00
Permodalan pasaran
1.20B CAD
Bilangan Purata
778.00
Nisbah P/E
-
Hasil dividen
-
Pertukaran utama
CNSX
Berita pasaran
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (CAD) | Dis 2025info | Perubahan T/T |
|---|---|---|
Hasil | — | — |
Perbelanjaan pengendalian | 6.74J | 325.10% |
Pendapatan bersih | -7.57J | -15,349.58% |
Margin untung bersih | — | — |
Pendapatan bagi setiap syer | -0.97 | -9,800.00% |
EBITDA | — | — |
Kadar cukai berkesan | — | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (CAD) | Dis 2025info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 89.05J | 53.80% |
Jumlah aset | 90.88J | 55.62% |
Jumlah liabiliti | 1.60J | 179.80% |
Jumlah ekuiti | 89.28J | — |
Syer tertunggak | 9.79J | — |
Harga kepada buku | 10.60 | — |
Pulangan pada aset | -19.23% | — |
Pulangan pada modal | -19.65% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (CAD) | Dis 2025info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | -7.57J | -15,349.58% |
Tunai daripada operasi | -5.82J | -289.18% |
Tunai daripada pelaburan | — | — |
Tunai daripada pembiayaan | 13.39J | -74.27% |
Perubahan bersih dalam tunai | 6.14J | -88.23% |
Aliran tunai bebas | -4.01J | -339.54% |
Perihal
Bright Minds Biosciences is an American pharmaceutical company which is developing serotonin 5-HT₂ receptor agonists for potential medical use.
It has a particular focus on serotonin 5-HT2C receptor agonists, for instance to treat rare epilepsies and other conditions. Another area of focus for the company is serotonergic psychedelics and non-hallucinogenic psychoplastogens.
The company was co-founded by Ian McDonald and Gideon Shapiro. The lead scientist at Bright Minds Biosciences was previously Alan Kozikowski. Bright Mind Biosciences was founded in 2017 and its headquarters are in New York City, New York. Wikipedia
Diasaskan
2017
Tapak web
Pekerja
26
